Novo Holdings Aerie Pharmaceuticals Inc Transaction History

Novo Holdings

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$5.64 - $9.8 $3.13 Million - $5.44 Million	-555,186 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$15.16 - $18.97 $3.54 Million - $4.42 Million	-233,224 Reduced 29.58%	555,186 $8.89 Million
Q1 2021 May 17, 2021	SELL	$13.12 - $20.9 $252,507 - $402,241	-19,246 Reduced 2.38%	788,410 $14.1 Million
Q2 2020 Aug 14, 2020	BUY	$12.0 - $16.13 $680,184 - $914,280	56,682 Added 7.55%	807,656 $11.9 Million
Q1 2020 May 15, 2020	BUY	$11.84 - $25.52 $958,305 - $2.07 Million	80,938 Added 12.08%	750,974 $10.1 Million
Q3 2019 Nov 14, 2019	BUY	$18.41 - $28.0 $1.84 Million - $2.8 Million	100,000 Added 17.54%	670,036 $12.9 Million
Q2 2019 Aug 14, 2019	BUY	$28.97 - $48.21 $3.46 Million - $5.75 Million	119,322 Added 26.47%	570,036 $16.8 Million
Q4 2018 Feb 14, 2019	BUY	$33.0 - $60.04 $1.39 Million - $2.53 Million	42,152 Added 10.32%	450,714 $16.3 Million
Q3 2018 Nov 14, 2018	BUY	$56.15 - $73.9 $15.8 Million - $20.9 Million	282,165 Added 223.24%	408,562 $0
Q2 2018 Aug 14, 2018	BUY	$47.85 - $70.45 $6.05 Million - $8.9 Million	126,397 New	126,397 $8.54 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

Stay updated on Novo Holdings with notifications on news.